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ABSTRACT 
Eye is the most sensitive organ of the body. Designing of ocular drug delivery system is the  most challenging field for pharmaceutical scientists 
as less than 5% of administered drug enters the eye due to the complicated anatomical structure of the eye, small absorptive surface and low 
transparency of the cornea, lipophilicity of corneal epithelium, pre corneal loss (due to nasolacrimal drainage), bonding of the drug with proteins 
contained in tear fluid, blinking, low capacity of conjunctival sac, that restricts the entry of drug molecule at the site of action and ultimately leads 
to poor ocular therapy. To improve ophthalmic drug bioavailability, there are considerable efforts directed towards newer drug delivery systems 
for ophthalmic administration. These novel drug delivery systems offer manifold advantages over conventional systems as they increase the 
efficiency of drug delivery by improving the release profile and also reduce drug toxicity. A lot of research going on in this area proves the fact 
that in situ gelling systems can be beneficial in the ocular drug delivery. In situ gel forming systems are drug delivery systems that are in solution 
form before administration in the body but once administered, undergo  in situ gelation, to form a gel triggered by external stimulus such as 
temperature, pH etc.  This review is to Specify a brief summary about in situ gels, various approaches for in situ gelling systems, different types of 
polymers used in in situ gels, their mechanisms of gel formation and evaluation of polymeric in situ gel. 
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1. INTRODUCTION 
The ocular drug delivery system is considered as crucial and 
challenging as human eye is an isolated organ where the 
delivery of drug is quite difficult. Moreover, the conventional 
ophthalmic formulations exhibit a short pre-corneal 
residence time and poor bioavailability due to rapid and 
extensive elimination of drugs from pre-corneal lachrymal 
fluid by solution drainage, lachrymation, and non-productive 
absorption by conjunctiva 1. In order to surpass the 
drawbacks associated with the conventional ophthalmic 
formulations, various attempts have been made towards the 
development of stable sustained release in situ gels. Newer 
research in ophthalmic drug delivery systems is directed 
towards incorporation of several drug delivery technologies, 
that includes to build up systems which not only extend the 
contact time of the vehicle at the ocular surface, but which at 
the same time slow down the elimination of the drug. In situ 
gel system is formulated as liquid preparation suitable to be 
instilled into eyes which upon exposure to the physiologic 
environment changes to gel, thus increasing the precorneal 
residence time of the delivery system, and enhances the 
ocular bioavailability of the drug 2 .The formation of gels 
depends on factors like change in a specific physico-chemical 
parameter (pH, temperature, ion-sensitive) by which the 
drug gets released in a sustained and controlled manner. 
There are various novel dosage forms like in situ gel, 
nanosuspension, nanoparticulate system, liposomes, 
niosomes, dendrimers, ocular iontophoresis, collagen shield, 
minidisc, ocular film, implants, ocuserts etc 3. Development 
of ocular drug delivery systems has always been challenging 
because of the drawbacks with ocular route like non-
productive absorption, impermeability of drugs to cornea, 
drainage, induced lachrymation and tear turn over. Topical 
application of drugs to the eye is the well established route 
of administration for the treatment of various ocular 
diseases like dryness, conjunctivitis, keratitis, eye flu etc. 
New approaches have been investigated for delivery of drugs 
to the eye by making use of polymers that pays a key role in 
delivery of drugs to the pre and intra ocular tissues 4. Such 
persistent attempts have resulted into achieving the increase 
in bioavailability and extending the duration of therapeutic 
action of ocular drug. Smart polymeric systems have proved 
to be promising means of delivering the drugs. These 
polymers undergo sol-gel transition after administered. They 
are in solution phase before administration, but gels under 
physiological condition. The ocular bioavailability of the 
drugs can be improved by prolonging their residence time in 
the cul-de-sac and by increasing their corneal permeability 5. 
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This review demonstrates a brief summary about in situ gels, 
various approaches for in situ gelling systems, also different 
types of polymers, their mechanisms of gel formation and 
evaluation of polymeric in situ gel. 
2. CLASSIFICATION OF OPHTHALMIC DRUG 
DELIVERY SYSTEMS 
    I. Conventional delivery systems 
 Eye drops 
 Ointments and Gels 
 Ocuserts and Lacrisert 
   II. Drug delivery to anterior segment 
 Contact lens 
 Cal du sac inserts 
 Subconjuctival/ Episcleral implants 
  III. Drug delivery to posterior segment 
 Intravitreal implants (e.g, Duraser Technology system, 
Novadu Technology, I- vatio TA, NT-501) 
 Injectable Particulate Systems ( RETAAC, Cortiject, 
Visudyne) 
  IV. Physical devices 
 Iontophoresis 
 Micro- electromechanical intra ocular drug delivery 
devices 
 V. Vesicular system 
 Liposomes 
 Niosomes 
 Discomes 
 Pharmacosomes 
VI. Controlled delivery systems 
 In situ gel systems/ Phase transition systems 
 Iontophoresis 
 Dendrimer 
 Contact lens 
 Collagen shield 
 Microemulsion  
 Nanosuspensions 
 Microneedle 
VII. Particulates 
 Nanoparticles 
 Microparticles 
 
VIII. Advanced delivery systems 
 Cell encapsulation 
 Gene therapy 
 Stem cell therapy 
 Protein and Peptide therapy 
 Scleral plug therapy 
 siRNA therapy 
 Oligonucleotide therapy 
 Aptamer 
3. FATE OF FORMULATION ADMINISTERED 
THROUGH EYE 6 
The general process of drug absorption into the eye from the 
precorneal area (dose site) following topical ocular 
administration is quite complex. The classical sequence of 
events involves drug instillation, dilution in tear fluid, 
diffusion through mucin layer, corneal penetration 
(epithelium, stroma, endothelium), and transfer from cornea 
to aqueous humor. Following absorption, drug distributes to 
the site of action (e.g., iris-ciliary body).  
Parallel absorption via the conjuctiva/sclera provides an 
additional pathway to eye tissues but, for most drugs, is 
minor compared with corneal absorption. Also, 
nonproductive, competing, and parallel pathways (e.g., 
nasolacrimal drainage or systemic absorption via the 
conjuctiva) work to carry drug away from the eye and limit 
the time allowed for the absorption process. Moreover, in 
some species, such as the rabbit, non-productive absorption 
into the nictitating membrane can occur. Figure 1 presents a 
summary of these precorneal events, along with a relatively 
simplified view of the kinetics in the cornea, aqueous humor, 
and anterior segment. 
4. IN SITU GELLING SYSTEM 
In situ gel forming systems are drug delivery systems that 
are in solution form before administration in the body but 
once administered, undergo gelation in situ, to form a gel 
triggered by external stimulus such as temperature, pH etc 
and release the drug in sustained or controlled manner. This 
novel concept of producing in situ gel was suggested for the 
first time in the early 1980s. Gelation occurs via the cross-
linking of polymer chains that can be achieved by covalent 
bond formation (chemical cross-linking) or non-covalent 
bond formation (physical cross-linking). In situ gel-forming 
systems can be described as low viscosity solutions that 
undergo phase transition in the conjunctival cul-de-sac to 
form viscoelastic gels due to conformational changes of 
polymers in response to the physiological environment. The 
rate of in situ gel formation is important because between 
instillation in the eye and before a strong gel is formed, the 
solution or weak gel is produced by the fluid mechanism of 
the eye 8. Both natural as well as synthetic polymers can be 
used for the fabrication of in situ gels 9. 
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Figure 1: Model depicting precorneal and ocular drug movement from topical instilled dose7. (BAB: blood-
aqueousbarrier, BRB: blood-retinalbarrier) 
 
 
Figure 2: In situ cross linking after instillation. 
 
5. ADVANTAGES OF IN SITU GELS 10 
 Less blurred vision as compared to ointment. 
 Decreased nasolacrimal drainage of the drug which may 
cause undesirable side effects due to systemic 
absorption (i.e. reduced systemic side effects).The 
possibility of administering accurate and reproducible 
quantities, in contrast to already gelled formulations 
and moreover promoting precorneal retention. 
 Sustained, Prolonged drug release and maintaining 
relatively constant plasma profile. 
 Reduced frequency of applications hence improved 
patient compliance and comfort. 
 Generally more comfortable than insoluble or soluble 
insertion. 
 Improved local bioavailability due to increased 
precorneal residence time and absorption. 
 Its production is less complex and thus lowers the 
investment and manufacturing cost. 
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6. MECHANISM OF IN SITU GELS 
The mechanism of in situ gels is based on following 
mechanisms: 
6.1 Based on physical mechanism 
6.1.1 Swelling: 
In this method of In situ gel formation material absorbs 
water from surrounding environment and expand to desired 
space. For example glycerol mono-oleate, which is polar lipid 
swells in water to form lyotropic liquid crystalline phase 
structures. It has some bioadhesive properties and can be 
degraded in vivo by enzymatic action 11. 
6.1.2 Diffusion: 
This method involves the diffusion of solvent from polymer 
solution into surrounding tissue which results in 
precipitation or solidification of polymer matrix. N-methyl 
pyrrolidone (NMP) has been shown to be useful solvent for 
such system 12. 
6.2 Based on chemical reaction mechanism 
Chemical reactions that results in situ gelation may involve 
precipitation of inorganic solids from supersaturated ionic 
solutions, enzymatic processes, and photo-initiated 
processes 13. 
7. POLYMERS USED IN THE FORMULATION OF IN 
SITU GELS 
7.1 Definition 
A polymer is a macromolecule composed of repeating 
structural units and these subunits are connected by 
covalent chemical bonds 14 
 7.2 Ideal characteristics of polymers 15 
The polymers used for in-situ gelling systems should have 
following characteristics: 
It should be biocompatible. 
It should be capable of adherence to mucus. 
The polymer should be capable of decreasing viscosity 
with increasing shear rate there by   offering lowered 
viscosity during blinking and stability of tear film during 
fixation. 
It should have pseudo plastic behaviour. 
It should be tolerable. 
It should have good optical activity. 
It should influence the tear behaviour. 
7.3 Polymers used in in-situ gels  
7.3.1 Carbopol 
It is a pH sensitive polymer. It is also called as carbomer, 
acrylic acid polymer, etc. 16 
 
Figure 3: Structure of Carbopol 17 
7.3.1.1 Properties of Carbopol 17 
1) Carbopol is a high molecular weight, cross linked 
polyacrylic acid derivative and has strongest mucoadhesive 
property. 
2) It is a water soluble vinyl polymer. 
3) It shows sol to gel transition, in aqueous solution, when 
the pH is raised above its pKa value of about 5.5. 
4) As the concentration of carbopol increases, its acidic 
nature may cause irritation to eye. Addition of cellulose will 
reduce polymer concentration and will also improve gelling 
property. 
Table 1: Various grades of carbopol 17 
Grade        Cross linking density 
         Carbopol 934                         Lowest 
         Carbopol 940                         Highest 
         Carbopol 981                         Intermediate 
 
Table 2: Uses of Carbopol 16 
            Use      Concentration (%) 
     Gelling agent               0.5-2.0 
     Emulsifying agent               0.1-0.5 
     Suspending agent               0.5-1.0 
 
7.3.1.2 Mechanism 
Mucoadhesive property of carbopol is due to four 
mechanisms of interaction between mucin and poly (acrylic 
acid)-electrostatic interaction, hydrogen bonding, 
hydrophobic interaction and inter diffusion.[18] Carbopol 
molecule is tightly coiled acidic molecule. Once dispersed in 
water, carboxylic group of the molecule partially dissociates 
to form flexible coil. Being a pH sensitive polymer, increase 
in solution pH results swelling of polymer. In acidic medium, 
it is in collapsed state due to hydrogen bonding, as the pH 
increases, electrostatic repulsion occur between the anionic 
groups, results gel swelling. The gelling effect is activated in 
two stages:dispersion and hydration of carbopol, 
neutralizing the solution by addition of sodium 
hydroxide,Triethanolamine, or potassium hydroxide 17. 
7.3.2 Poloxamer 
It is a temperature sensitive polymer. It is commercially 
called as Pluronic. 
 
Figure 4: Structure of poloxamer 
7.3.2.1 Properties of Poloxamer 
1) It is a water soluble tri-block copolymer consisting of two 
polyethylene oxide (PEO) and polypropylene oxide (PPO) 
core in an ABA configuration. 
2) Polypropylene oxide is the hydrophobic central part 
which is surrounded on both sides by hydrophilic 
Polyethylene oxide. 
Majeed et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(1):337-347 
ISSN: 2250-1177                                                                                  [341]                                                                                 CODEN (USA): JDDTAO 
3) It has good thermal setting property and increased drug 
residence time. 
4) It gives colourless, transparent gel 17. 
5) Concentrated aqueous solutions of Poloxamer form 
thermoreversible gels 18. 
Table 3: Various grades of poloxamer 17 
       Poloxamer    Molecular weight 
              124                                                                             2200 
              188                8400 
              237                  7959 
              338              14600 
              407              12600 
 
7.3.2.2 Uses of Poloxamer 
a) Gelling Agent. 
b) Emulsifying Agent. 
c) Solubilizing Agent. 
7.3.2.3 Mechanism 
At room temperature (25ºC), poloxamer behaves as viscous 
liquid and is transformed to transparent gel when 
temperature increases (37ºC). At low temperature, it forms 
small micellar subunit in solution and increase in 
temperature results increase in viscosity which leads to 
swelling to form large micellar cross linked network. 
 
Figure 5: Gelling mechanism of Poloxamer 
7.3.3 Gellan Gum 
It is an ion-sensitive polymer. It is also known as 
Gelrite®(trade name). 
   
 
Figure 6: Structure of Gellan gum 
7.3.3.1 Properties of Gellan Gum 
1) Gellan gum is a linear,anionic heteropolysaccharide 
secreted by the microbe Sphingomonas elodea 17,18. 
2) The backbone of the polymer consists of 
glucose,glucoronic acid and rhamnose in the molar ratio 
2:1:1.These are linked together to give a tetrasaccharide 
repeat unit. 
3) Gelrite is deacetylated gellan gum, obtained by treating 
gellan gum with alkali to remove the acetyl group in the 
molecule. 
4) Upon instillation, gelrite forms gel due to the presence of 
calcium ions. 
5) The gelation involves the formation of double helical 
junction zones followed by aggregation of double helical 
segment to form three dimensional networks by 
complexaton with cations and hydrogen bonding with water. 
6) It is widely used in ophthalmology because of its 
thixotropy,thermo plasticity and pseudo plasticity. 
7.3.3.2 Uses of Gellan Gum 
a) Thickening Agent. 
b) Gelling Agent. 
c) Stabilizing Agent. 
7.3.3.3 Mechanism 
Gellan gum produce a cation induced in situ gelation (Ca2+, 
Mg 2+, K+, Na+) due to the cross linking between negatively 
charged helices and mono or divalent cations (Na+, Ca+, 
Mg+). Divalent ions are superior in promoting gelation as 
compared to monovalent cations. Gelation prolongs the 
residence time of drug at absorption site and bioavailability 
of the drug is increased. 
7.3.4 Sodium Alginate 
It is an ion-sensitive polymer. It is also known as algin, 
alginic acid, sodium salt, E401, 
Kelcosol,Keltone,Protanal,sodium polymannuronate 16. 
 
Figure 7: Structure of Sodium Alginate 
7.3.4.1 Properties of Sodium Alginate 17 
1) Sodium alginate is a gum extracted from brown algae. 
2) It is a salt of alginic acid. 
3) It is a linear block polysaccharide consisting of two types 
of monomers-β-D-Mannuronic acid and α-L-glucouronic acid 
residues joined by 1,4-glycosidic linkages. 
4) It exhibits good mucoadhesive property due to presence 
of carboxylic group. 
5) It is biodegradable and non-toxic. 
6) It has high molecular weight of 20 to 600 kDa. [14]                                                                              
7.3.4.2 Uses of Sodium Alginate 16 
a) Thickening Agent. 
b) Suspending Agent. 
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7.3.4.3 Mechanism 17 
The monomers of alginate (β-D-mannuronic acid (M) and α-
L- glucuronic acid (G) are arranged as M-M block or G-G 
block with alternating sequence (M-G) block. Upon 
interaction of G block of polymer with calcium moieties, 
formation of homogenous gel takes place. Mechanical 
strength and porosity of hydrogel depends on G: M ratio, 
type of cross linker used and concentration of alginate 
solution. 
7.3.5 Chitosan 
 
Figure 8: Structure of Chitosan 
7.3.5.1 Properties of Chitosan 
1) Chitosan is a cationic polysaccharide which consists of 
copolymers of glucosamine and N-acetyl glucosamine, these 
are natural polymer obtained by deacetylation of chitin 17. 
2) Chitosan has mucoadhesive property due to electrostatic 
interactions between positively charged amino group and 
negatively charged mucin 17. 
3) It is a polycationic polymer and also called as ophthalmic 
vehicle 19. 
4) It is biodegradable, biocompatible and non-toxic polymer 
19. 
5) It exhibits pseudoplastic and viscoelastic behaviour 19. 
6) It has good antibacterial and bioadhesive property 17,19. 
7) It has ability to convert into hydrogel at ocular pH 20. 
7.3.5.2 Mechanism 
The mucoadhesive property of chitosan is due to the 
formation of ionic interaction between the positively 
charged amino groups of chitosan and negatively charged 
sialic acid residues of mucin. It is used as viscosity ehancing 
agent in artificial tear formulations because of its 
bioadhesive, hydrophilic and good spreading properties. 
7.3.6 Hydroxy Propyl Methyl Cellulose (HPMC) 
It is a temperature sensitive polymer. It is also known as 
Hypromellose, Methocel etc 16. 
 
Figure 9: Structure of HPMC 17 
7.3.6.1 Properties of HPMC 
1) It is water soluble cellulose ether 21. 
2) Widespread acceptance of HPMC due to 22: 
a) Solubility characteristics of the polymer in organic and 
aqueous solvent system. 
b) Non-interference with drug availability. 
c) Flexibility and absence of taste and odour. 
d) Stability in the presence of heat, light, air or reasonable 
levels of moisture. 
3) It is composed of glucan chain with repeating β-(1,4)-D-
glucopyranose unit 17. 
4) It increases its viscosity when temperature increases 17. 
5) At low concentrations (1-10 wt.%) aqueous solutions of 
HPMC are liquid at low temperature but gel upon heating 23. 
6) It shows phase transition between 75ºC and 90ºC.These 
phase transition temperatures can be lowered by chemical 
or physical modifications 23. 
7) By reducing the hydroxyl propyl molar substitution of 
HPMC, its transition temperature can be lowered to 40⁰C. 
7.3.6.2 Uses of HPMC 16 
a) Thickening Agent. 
b) Suspending Agent. 
c) Stabilizing Agent. 
Table 4: Commercial grades of HPMC 23 
Polymer Grade  Viscosity mPas) 
 
 
HPMC 
Methocel  
A4MP  4000 
A15-LV  15 
A15CP 1500 
A4CP  400 
 
7.3.6.3 Mechanism 23 
Gelation of HPMC solutions is primarily caused by the 
hydrophobic interaction between molecules containing 
methoxy substitution. At low temperatures, the 
macromolecules are hydrated, and there is little polymer-
polymer interaction other than simple entanglement. As the 
temperature is raised, the polymers gradually lose their 
water of hydration, which is reflected by a decline in relative 
viscosity. Eventually, when sufficient but not complete 
dehydration of the polymer occurs, polymer–polymer 
associations take place, and the system approaches an 
infinite network structure, as reflected experimentally by a 
sharp rise in relative viscosity. This sol–gel transformation 
has been exploited to design in situ gelling systems. These 
systems exhibited low viscosity at 23 °C and formed soft gels 
at 37ºC. 
8. APPROACHES FOR IN SITU GELLING SYSTEM: 24 
The various approaches for in situ gelling system are: 
 Temperature induced in situ gel systems 
 pH induced in situ gel systems 
 Ion activated systems 
     8.1 Temperature triggered in situ gelling system:  
In drug delivery research temperature sensitive in situ gels 
are probably the most commonly studied class of 
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environment- sensitive polymer systems. In this gelling 
system polymers are liquid at room temperature (20-25°C) 
and undergoes gelation at physiological temperature (35-
37°C) 25. An ideal temperature triggered gelling polymer 
solution should remain liquid below its low critical solution 
temperature (LCST) and up to its upper critical solution 
temperature (UCST) and should transform into gel on 
increase of the surrounding temperature. There is gradual 
desolvation of the polymer and increased micellar 
aggregation (entanglement of the polymeric network) 26,27. 
For an optimum temperature triggered in situ gelling 
solution, the phase transition temperature should be more 
than room temperature (25°C) so that it can be easily 
administered to eye and gelled at precorneal temperature 
(35°C) without having any effect of tear fluid dilution even at 
concentration as low as 5% w/v 28. Figure 10 shows the in 
situ gelation of the temperature triggered polymers.
 
 
 
Figure 10: Schematic of temperature triggered in situ gelling system 29 
 
8.2 pH triggered in situ gelling system: pH triggered in 
situ gelling systems are solutions, which upon exposure to 
the pH of the lachrymal fluid converts into the gel phase e.g. 
such as cellulose acetate phthalate and Carbopol [28]. The 
pH sensitive polymers contain either weakly acidic or basic 
groups along the backbone of the polymer, these either 
release proton or accept free proton in response to change in 
pH. At specific pH there is Electrostatic, hydrophobic 
interaction and Hydrogen bonding takes place, hence leads 
to inter-diffusion and a conformational change in the 
polymer results in its swelling. Hence sol to gel transition is 
pH triggered 30. Fig. 11 shows the in situ gelling phenomena 
by pH modification of the system. 
 
             
 
Figure 11: pH triggered in situ gelling system 29 
 
8.3 Ion triggered in situ gelling system: In ion triggered in 
situ gelling system solution viscosity increases upon 
exposure to ionic concentration of the tear fluids 28. It is also 
called osmotically induced gelation. Ion sensitive polymers 
are able to crosslink with cations (monovalent, divalant) 
present in lacrimal fluid on ocular surface and enhance the 
retention time of drug 30. 
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Figure 12: Schematic of mechanism of ion triggered in situ gelling system 29 
  
 
Figure 13: Overview on in situ gel 
 
9. Evaluation of Ocular in situ gel  
Ocular in situ gel can be tested for various parameters in 
order to ensure that prepared formulation satisfy safety 
guidelines for ocular drug delivery system (ODDS).  
9.1 Visual appearance and clarity Visual appearance and 
clarity of prepared in situ formulation is checked for 
presence of any particulate matter under fluorescent light 
against a white and black back ground 31. 
9.2 pH  pH affects both solubility as well as stability of drug 
in ophthalmic formulations. It should be such that the 
formulation will remain stable at that pH at the same time 
there would no irritation to the patient upon administration. 
It is measured by digital pH meter 32. 
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9.3 Gelling capacity Gelling capacity of formulation is 
determined by placing a drop of the formulation in a vial 
containing 2.0 ml of freshly prepared simulated tear fluid 
and time taken for its gelling is noted 33. 
9.4 Isotonicity Isotonicity is important characteristics of 
ophthalmic formulation which has to be maintained to 
prevent any tissue damage or irritation to the eye. It refers to 
the osmotic pressure exerted by salts in aqueous solution. 
Ophthalmic formulation must possess osmotic pressure 
within the range of 290-310 mOsmol/kg. Tonicity is 
measured by using osmometer 34,35.  
9.5 In vitro drug release study  
In vitro drug release study is done by using Franz diffusion 
cell. In receptor compartment freshly prepared artificial tear 
fluid (ATF) is placed. Dialysis membrane is placed in 
between receptor and donor compartments. Whole assembly 
is kept on the thermostatically controlled magnetic stirrer to 
simulate in vivo conditions and temperature of medium is 
maintained at 37oC ± 0.5oC. Medium is continuously stirred 
at 20 rpm. 1ml of formulation is placed in donor 
compartment. Sample (0.5ml) is withdrawn at 
predetermined time interval and same is replaced by ATF. 
Samples are analysed either on UV spectrophotometer or 
HPLC 36, 37.  
9.6 Rheological studies Brookfield viscometer is mainly 
used for determination of Viscosity of ophthalmic in situ gels. 
Viscosity is measured before and after gelation by increasing 
angular velocity gradually from 0.5 to 100 rpm 38. 
9.7 Texture analysis The consistency, firmness, and 
cohesiveness of in situ gel are assessed by using texture 
profile analyzer. This mainly indicates gel strength and 
easiness in administration. Texture analysis provides 
information on hardness, compressibility and adhesiveness 
which can be correlated with various parameters like ease of 
removal from container, good spreadability on corneal 
surface and adherence to mucous layer in order to prolong 
residence time 39. 
9.8 Transcorneal permeability study  
Transcorneal permeability of drug is evaluated by using goat 
eye cornea. The fresh whole eyeball of goat is obtained from 
local butcher’s shop and transported in laboratory in normal 
saline solution (4oC). Cornea is then carefully excised along 
with 2-4 mm of surrounding sclera tissue and wash with 
saline solution. Excise cornea is place in between donor and 
receptors compartment of Franz diffusion cell in such a way 
that epithelial surface face the donor compartment. Receptor 
compartment is filled with freshly prepared artificial tear 
fluid (ATF). Whole assembly is placed on thermostatically 
controlled magnetic stirrer, temperature (37oC ± 0.5oC) as 
well as stirring rate (20 rpm) is maintained. 1ml of prepared 
formulation is placed in donor compartment. Samples 
(0.5ml) are withdrawn at predetermined time interval of 1hr 
to 5hr and same volume is replaced by ATF. Samples are 
then diluted upto 10ml and analysed on either UV 
spectrophotometer or HPLC 40, 41. 
9.9 Ocular irritation study As there is ban on Draize study 
in many countries ocular irritation study of in situ 
formulation can be performed by one of the following 
method. 
9.9.1 Histological study To evaluate effect of in situ 
formulation on corneal structure and study the irritation 
potential, corneas are removed from the eyes of freshly 
sacrificed goat and incubated at 37oC for 5 hrs in 
formulation. Sodium dodecylsulfate (SDS) solution in 
phosphate buffer saline (PBS) 0.1% (w/w) is used as the 
positive control. After incubation, corneas are washed with 
PBS and immediately fixed in formalin (8%, w/w). Tissues 
are dehydrated in an alcohol gradient, placed in melted 
paraffin and solidified in block form. Cross sections are cut, 
stained with haematoxylin and eosin (H&E). Cross sections 
are observed microscopically for any modifications 42. 
9.9.2 Hen’s Egg Test-Chorioallantoic Membrane (HET-
CAM) HET-CAM test is performed by incubating the eggs for 
10 days at 37oC and relative humidity of about 70% with 
automatic turning once per hour. After incubation period, a 
portion of each egg shell is removed and a drop of water is 
placed onto the air sack membrane to avoid capillary 
damage during its removal. The CAM is then carefully 
exposed to 0.1 ml or 0.1 gm of test substances, which is 
washed-off with normal saline solution after 30 sec of 
exposure. Simultaneously, CAM is exposed to saline solution 
(negative control) and 1% SDS solution (positive control). 
Each CAM is observed microscopically after 5 minutes for 
haemorrhage, lysis and coagualtion. An irritation score (IS) is 
calculated for each CAM by using following formula;   = 
301−      ℎ     
300×5+(301−     )300×7+301−           300×9 
Irritation score is given according to following scheme; 0 = 
no reaction; 1 = slight reaction; 2 = moderate reaction; 3= 
severe reaction 43, 44. 
9.10 In vivo Scintigraphy Studies Gamma scintigraphy is a 
well-established technique for in vivo evaluation of 
ophthalmic retention time. Although the rabbit is the 
commonly recommended animal model for evaluation of 
ophthalmic formulations, but human volunteers are 
preferred for this study due to physiological differences 
between rabbits and humans, especially the blinking rate 45. 
9.11 Accelerated stability study A stability study for in situ 
formulation is carried out as per ICH guidelines to determine 
the physical stability of the formulation under accelerated 
storage conditions. Formulation is subjected to elevated 
temperatures and humidity conditions of 25±1°C/ 60%RH, 
30±1°C/ 65%RH and 40 ± 2oC/ 75 ± 5 % RH. Samples are 
withdrawn at the end of 0, 30, 60 and 90 days and then 
evaluated for active drug content 46. 
9.12 Sterility testing Sterility testing of ophthalmic 
preparations is very important evaluation parameter. The 
sterility test is performed according to Indian 
Pharmacopoeia. Direct inoculation method is used; 2 ml of 
liquid from test container is removed with a sterile pipette or 
with a sterile syringe or a needle. The test liquid is then 
aseptically transferred to fluid thioglycolate medium (20 ml) 
and soyabean-casein digest medium (20 ml) separately. The 
liquid is mixed with the media. The inoculated media is 
incubated for not less than 14 days at 30°C to 35°C in the 
case of fluid thioglycolate medium and 20°C to 25°C in the 
case of soyabean-casein digest media. 
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Table 5: Marketed Products of ophthalmic In situ gels 47 
 
  Product Name 
     
   Drug Used 
 
 Mfg. Company 
   
Timoptic-XE  
  
   Timolol maleate  
 
Merck and Co.Inc  
 
Cytoryn  
  
   Interleukin-2(IL-2)  
 
Macromed 
 
Azasite 
         
   Azithromycin  
 
InSite Vision 
 
AktenTM  
    
   Lidocaine hydrochloride 
 
Akten 
 
Virgan 
            
   Ganciclovir 
Spectrum Thea Pharmaceuticals 
 
Pilopine HS 
   
    Pilocarpine hydrochloride 
 
Alcon Laboratories Inc. 
 
CONCLUSION  
Ocular drug delivery system is burgeoning field in which 
most of the researchers are taking challenges to combat 
various problems associated to this delivery. Steady 
advancement in the understanding of principles and 
processes governing ocular drug absorption and disposition 
and continuing technological advances have surely brought 
some improvements in the efficacy of ophthalmic delivery 
systems. The primary requirement of a successful controlled 
release product focuses on increasing patient compliance 
which the insitu gels offer. In situ gelling systems are 
promising ocular delivery systems because they can 
overcome the drawbacks associated with conventional 
ocular dosage forms thus in the recent years ophthalmic in 
situ gelling drug delivery systems have drawn much 
attention of researchers. They are easy to administer with 
improved patient compliance. The principal advantages of 
these systems are the possibility of administering accurate 
and reproducible quantities of drugs, increased precorneal 
contact time, prolonged drug release, drug delivery to deeper 
tissues, and reduced frequency of administration. Further, 
drug loaded nanoparticles, liposomes or other colloidal drug 
carriers can also be incorporated in these systems to obtain 
sustained drug delivery in a much improved and effective 
manner. Future use of biodegradable and water soluble 
polymers for the in situ gel formulations can make them 
more acceptable and excellent drug delivery systems. 
Moreover, in situ gels have ease of commercialization which 
adds advantage from industrial point of view. 
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